midastouch017 Saturday, 03/28/15 07:23:02 AM Re: midastouch017 post# 54 Post # of 87 H2 2015 Data release from analysis of Phase II glaucoma trial During the first half of 2015, Can-Fite expects to announce results from its Phase II study of CF101 in the treatment of glaucoma. The 88 patient study is planned to be conducted in two European countries by Can-Fite's subsidiary OphthaliX Inc. (OPLI). The global glaucoma market was estimated by GlobalData to be worth approximately $3 billion in 2010 and CF101 is one of only a few oral drugs developed for glaucoma. The market currently consists primarily of generic eye drop drugs. Oral administration is expected to improve patient compliance.